NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-079-2018-0-US-02 ANTIBODIES AND METHODS FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION US DIV 18/796,697 Pending
NICHD E-003-2014-0-US-03 MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND TO MATRILIN 3 AND THEIR USE US CON 18/796,807 Pending
NIAID E-047-2022-0-BR-01 Human Monoclonal Antibodies That Broadly Target Coronaviruses BR National Stage BR112024016168-4 Pending
NIAID E-047-2022-0-BH-01 Human Monoclonal Antibodies That Broadly Target Coronaviruses BH National Stage 2024-02-28 Pending
NIAID E-047-2022-0-OM-01 Human Monoclonal Antibodies That Broadly Target Coronaviruses OM National Stage OM/P/2024/000492 Pending
NEI E-015-2019-0-SG-12 BIODEGRADABLE TISSUE REPLACEMENT IMPLANT AND ITS USE SG DIV 10202402344U Pending
NIAID E-047-2022-0-KW-01 Human Monoclonal Antibodies That Broadly Target Coronaviruses KW National Stage 2024/003073 Pending
NIAID E-047-2022-0-IL-01 Human Monoclonal Antibodies That Broadly Target Coronaviruses IL National Stage 314799 Pending
NIAID E-047-2022-0-US-02 Human Monoclonal Antibodies That Broadly Target Coronaviruses US National Stage 18/835,912 Pending
NIAID E-531-2013-2-BR-01 Epstein-Barr Virus Vaccines BR DIV BR122024015865-5 Pending
NCATS E-057-2022-0-EP-01 ESTRADIOL PRODRUGS AND METHODS OF USE THEREOF EP National Stage 23737785.8 Pending
NIAID E-047-2022-0-MY-01 Human Monoclonal Antibodies That Broadly Target Coronaviruses MY National Stage PI2024004517 Pending
NCI E-176-2014-0-JP-02 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS JP DIV 2024-126652 Pending
NIAID E-083-2017-0-US-06 GLYCAN-MASKED ENGINEERED OUTER DOMAINS OF HIV-1 GP120 AND THEIR USE US DIV 18/793,025 Pending
NICHD E-058-2021-0-US-03 La Protein As A Novel Regulator Of Osteoclastogenesis US DIV 18/791,272 Pending
NCI E-264-2011-0-EP-01 Delivery Of Packaged RNA To Mammalian Cells EP DIV 24191846.5 Pending
NICHD E-026-2019-0-US-02 POLYPEPTIDES, NUCLEIC ACID MOLECULES, COMPOSITIONS, AND RELATED METHODS US DIV 18/786,697 Pending
NIBIB E-157-2023-0-PC-01 METHOD AND SYSTEM FOR RAPID SPECTRAL UNMIXING USING SPECTRALLY INTERPOLATED BACKGROUND REDUCTION PCT PCT PCT/US2024/039976 Pending
NCI E-040-2012-0-KR-01 CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN KR DIV 2024-7025571 Pending
NHLBI E-035-2022-0-US-02 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) US National Stage 18/833,627 Pending
NHLBI E-035-2022-0-JP-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) JP National Stage 2024-544466 Pending
NCI E-042-2014-0-AU-01 Chimeric Antigen Receptors Targeting CD-19 AU DIV 2024205043 Pending
NCI E-025-2022-0-AU-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF AU National Stage 2023221836 Pending
NHLBI E-035-2022-0-EP-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) EP National Stage 23707534.6 Pending
NCI E-183-2017-0-JP-02 ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS JP DIV 2024-118255 Pending
NCI E-237-2017-2-CR-03 T CELL RECEPTORS RECOGNIZING MUTATED P53 CR DIV 2024-0303 Pending
NHLBI E-035-2022-0-CA-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) CA National Stage 3243219 Pending
NCI E-237-2017-2-CR-01 T CELL RECEPTORS RECOGNIZING MUTATED P53 CR DIV 2024-0301 Pending
NCI E-237-2017-2-CR-02 T CELL RECEPTORS RECOGNIZING MUTATED P53 CR DIV 2024-0302 Pending
NIA E-024-2022-0-US-02 GINGERENONE A PRODRUGS AS SENOTHERAPEUTICS AND METHODS OF USE US National Stage 18/832,248 Pending
NIA E-024-2022-0-US-03 GINGERENONE A PRODRUGS AS SENOTHERAPEUTICS AND METHODS OF USE US CIP 18/780,981 Pending
NCATS E-022-2022-0-EP-01 METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA
FROM BIOLOGICAL ASSAYS 		EP National Stage 22854698.2 Pending
NCI E-056-2023-0-PCT-01 IDENTIFICATION OF NOVEL SEQUENCES OF THE ERVMER34-1 HUMAN ENDOGENOUS RETROVIRAL SEQUENCE FAMILY, AND MODIFICATION OF THOSE SEQUENCES FOR A MORE EFFECTIVE ANTI-CANCER VACCINE AND OTHER POTENTIAL ANTI-CANCER THERAPIES PCT PCT PCT/US2024/039057 Pending
NHLBI E-035-2022-0-IL-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) IL National Stage 314428 Pending
NIAID E-165-2023-0-PC-02 BISPECIFIC ANTIBODIES THAT BROADLY TARGET CORONAVIRUSES PCT PCT PCT/US2024/038583 Pending
NIDDK E-162-2023-0-PC-01 5-HT2B SEROTONIN RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF PCT PCT COMB PCT/US2024/038286 Pending
NCI E-202-2023-0-PC-01 KINASE INHIBITORS PCT PCT PCT/US2024/038376 Pending
NIAAA E-189-2021-0-IL-01 CANNABINOID RECEPTOR MODULATING COMPOUNDS IL National Stage 314385 Pending
NHLBI E-342-2013-0-US-02 Human IPSC-derived Vascular-related And Hematopoetic Cells For Therapies And Toxicology/drug Screenings US CON 18/775,257 Pending
NCI E-045-2022-0-US-02 METHOD OF HUMAN LEUKOCYTE ANTIGEN LOSS OF HETEROZYGOSITY DETECTION IN LIQUID BIOPSIES US National Stage 18/729,138 Pending
NCI E-193-2017-0-US-04 Ultrasound Sensitive Peptide Particles For Spatially Resolved Molecule Delivery US DIV 18/771,481 Pending
NIAID E-095-2019-0-US-02 HIV RNA VACCINES US DIV 18/771,978 Pending
NCI E-133-2016-0-JP-13 FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS USING SAME JP DIV 2024-112931 Pending
NEI E-212-2015-0-US-02 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS US CON 18/769,320 Pending
NCI E-125-2023-0-PC-01 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS PCT PCT PCT/US2024/037349 Pending
NCI E-188-2023-0-PC-01 HUMANIZED 40H3 ANTIBODY PCT PCT PCT/US2024/037091 Pending
NCI E-051-2022-0-US-02 METHODS OF PREDICTING PATIENT TREATMENT RESPONSE AND RESISTANCE VIA SINGLE-CELL TRANSCRIPTOMICS OF THEIR TUMORS US National Stage 18/727,094 Pending
NCI E-184-2009-0-US-05 Combination Immunotherapy Compositions And Methods US CON 18/764,645 Pending
NIAAA E-190-2021-0-EP-01 Thiol-moeity Containing Cannabinoid Receptor Modulating Compounds EP National Stage 22847074.6 Pending
NIDDK E-051-2021-0-EP-02 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS EP DIV 24185703.6 Pending